Filed with ASX · · 2 pages · English
Noxopharm Ltd. has announced an investor webinar scheduled for November, featuring updates on its SOF-SKN™ extension study and the Sofra™ technology platform. The event aims to engage shareholders and investors in discussions about the company's clinical development programs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Noxopharm Investor Webinar Sydney, 6 November 2026: Australian clinical-stage biotechnology company Noxopharm Limited (ASX:NOX) invites shareholders and investors to attend an investor webinar with CEO Dr Olivier Laczka and Professor Michael Gantier of the Hudson Institute of Medical Research on...
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm